Font Size
A
A
A
...
5
...

Current and Future Medications for Hepatitis C (cont.)

What is the dosage for DAAs?

Victrelis (oceprevir)

  • 800 mg is taken three times a day, and simeprevir 150 mg is taken once daily with food, combined with ribavirin.

Technivie (ombitasvir/paritaprevir/ritonavir)

  • Technivie is given with ribavirin for 12 weeks for genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.
  • Each tablet contains 12.5 mg ombitasvir, 75 mg paritaprevir and 50 mg ritonavir.
  • Two tablets are taken every morning, with ribavirin dosed by weight: 1000 mg per day for patients weighing less than 75 kg, and 1200 mg per day for those 75 kg and over; this is divided into a twice-daily dose with food.

Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir)

  • Viekira is used for genotype 1a or 1b chronic hepatitis C, including people with or without cirrhosis and no liver failure symptoms.
  • Viekira Pak is ombitasvir 12.5 mg, paritaprevir 75mg, ritonavir 50 mg in each tablet, packaged with dasabuvir 250mg tablets.
  • It is dosed as two ombitasvir, paritaprevir, ritonavir tablets once daily (in the morning) and one dasabuvir tablet twice daily (morning and evening), along with a meal.
  • It is given with or without ribavirin (dosed as above).
  • Genotype 1a is most resistant to treatment, so Viekira is given with ribavirin for 12 weeks if there is no cirrhosis, or 24 weeks if there is cirrhosis.
  • Genotype 1b is usually treated with Viekira alone for 12 weeks if no cirrhosis; with cirrhosis (or in some cases of prior treatment) it must be given with ribavirin for 12 weeks.
  • Viekira may also be used in liver transplant recipients.

Zepatier (grazoprevir and elbasvir)

  • Zepatier is elbasvir 50 mg and grazoprevir 100 mg in one tablet, and it is given for chronic hepatitis C genotype 1 or 4 with or without cirrhosis, and with or without certain resistance mutations.
  • While Zepatier can be given to patients who have never been treated, it offers a special treatment option to patients who have failed treatment with PegIFN/RBV, as well as protease inhibitors.
  • One tablet taken orally once daily with or without food, and may be given with or without RBV as above, depending on the individual patient.
  • Patients who have been treated before or have certain resistance mutations ("NS5A") are dosed differently and for longer than other patients.
  • Genotypes 1a with NS5A mutations and genotype 4 that has failed PegIFN/RBV are treated with Zepatier and RBV for 16 weeks.
  • All others are treated for 12 weeks, with addition of RBV in those with genotype 1 who have failed PegIFN/RBV and protease inhibitors.

Sovaldi (sofosbuvir)

  • Sovaldi is used to treat chronic hepatitis C genotype 1 or 4 with PegIFN/RBV, or genotype 2 or 3 with RBV alone.
  • One 400mg tablet is taken once orally with or without food.
  • All genotypes except for three are treated for 12 weeks; genotype 3 is treated for 24 weeks.
  • Advantages of Sovaldi includes the option to treat genotype 1 patients who are not candidates for using interferons; these patients may take Sovaldi alone for 24 weeks.
  • Sovaldi can also be given with RBV for up to 48 weeks to patients awaiting a liver transplant, as an attempt to prevent HCV infection of the new liver.

Harvoni (sofosbuvir and ledipasvir)

  • Harvoni is a nucleotide analog inhibitor combination of ledipasvir 90 mg/sofosbuvir 400 mg in one tablet.
  • It is taken orally once daily with or without food.
  • Harvoni is used to treat chronic hepatitis C genotypes 1, 4, 5 or 6.
  • All genotypes may be treated with Harvoni alone regardless of prior treatment and with or without cirrhosis. With the addition of RBV, however, Harvoni extends the option of treatment to patients with genotype 1 who have cirrhosis and liver failure (decompensated cirrhosis).
  • All treatment durations are 12 weeks with the exception of genotype 1 with cirrhosis.

Daklinza (daclatasvir)

  • Daklinza is an NS5A inhibitor used to treat genotype 3 chronic hepatitis C. It is given combined with Sovaldi (sofosbuvir).
  • Either 30mg or 60mg tablets are given orally once a day with sofosbuvir for 12 weeks for patients without cirrhosis, with the exact dose depending on drug interactions with other medications the patient may be taking.
  • There is no specific duration offered for patients with cirrhosis, but there is no specification against using this drug in people with even severely impaired liver function.
Medically Reviewed by a Doctor on 4/21/2016
Pharmacy Author:

Must Read Articles Related to Current and Future Medications for Hepatitis C

Hepatitis C
Hepatitis C Hepatitis C is inflammation of the liver caused by ...learn more >>
Liver (Liver Disease, Anatomy, and Function)
Liver The liver is the largest solid organ in the body, and is actually an gland. The liver has a wide variety of critical functions such as manufacturing proteins an...learn more >>
Liver Blood Tests
Liver Blood Tests Liver blood tests, or liver function tests, are used to detect and diagnose disease or inflammation of the liver. Elevated aminotransferase (ALT, AST) levels ar...learn more >>

Patient Comments & Reviews

The eMedicineHealth doctors ask about Hepatitis C Medications:

Hepatitis C Medications - Experience

Please share your experience with hepatitis C drugs.

Hepatitis C - Direct-Acting Agents

Please share your experience with DAA drugs (type of drug, any side effects, etc.). Also, is your hepatitis cured?

Hepatitis C - Interferons

Please share your experience with interferons to treat hep C (for example, side effects, drug interactions, etc.).

Hepatitis C - Ribavirin

Please share your experience with ribavirin (for example, side effects, drug interactions, etc.).


Read What Your Physician is Reading on Medscape

Hepatitis C »

The World Health Organization (WHO) estimates 170 million individuals worldwide are infected with hepatitis C virus (HCV).

Read More on Medscape Reference »


Medical Dictionary